NurExone Exosomes
NurExone Exosomes
  • NurExone Biologic (NRX) has received a notice of allowance from the United States Patent and Trademark Office for U.S. Patent Application NO. 17/042,44
  • The patent covers and protects NurExone Exo-PTEN technology and its drug composition, as well as methods for non-invasive intranasal administration of exosome-based treatment
  • The company plans to file additional patent applications with the USPTO as well as additional international patent applications (PCT)
  • NurExone Biologic Inc. is a pharmaceutical company developing a platform for biologically-guided ExoTherapy to be delivered, non-invasively, to patients who suffered traumatic spinal cord injuries
  • NurExone Biologic Inc. was unchanged at $0.385 at 3:09 PM ET

NurExone Biologic (NRX) has received a notice of allowance from the United States Patent and Trademark Office (USPTO).

The notice of allowance is for U.S. Patent Application NO. 17/042,44.

The patent covers and protects NurExone Exo-PTEN technology and its drug composition, as well as methods for non-invasive intranasal administration of exosome-based treatment.

The patent discloses and claims groundbreaking inventions and methods in exosome technology. This includes the pharmaceutical compositions comprising extracellular vesicles, including exosomes, loaded with an exogenous inhibitor of phosphatase and tensin homolog (PTEN) inhibitor, as well as a method for treating neuronal injury or damage, including intranasal administration.

NurExone plans to file additional patent applications with the USPTO as well as additional international patent applications (PCT) in order to further strengthen NurExone’s intellectual property portfolio.

The patent was submitted by the Technion-Israel Institute of Technology and Ramot, a Tel Aviv University’s technology transfer company, and is part of NurExone’s licensed intellectual property portfolio.

“We are delighted that the USPTO has determined that the patent application covering our proprietary drugs and methods of administration satisfies the requirements for patentability,” said Dr. Lior Shaltiel, CEO of NurExone.

“The patent will enable us to strengthen the IP barrier protecting our core technology, including the source of the cells, loaded siRNA and method of administration,” he added.

Furthermore, at the company’s annual and special shareholders’ meeting held on December 19, 2022, among other decisions, the company’s shareholders approved the company’s equity incentive plan, which replaces the option plan of the company previously in effect.

NurExone Biologic Inc. is a pharmaceutical company developing a platform for biologically-guided ExoTherapy to be delivered, non-invasively, to patients who suffered traumatic spinal cord injuries.

NurExone Biologic Inc. was unchanged at $0.385 at 3:09 PM ET.


More From The Market Online

Thomson Reuters expands its GenAI assistant

Thomson Reuters (TSX:TRI) has revealed the expanded vision for its professional-grade GenAI assistant, CoCounsel.

InZinc reports high-grade barite results from Indy project

InZinc Mining (TSXV:IZN) reports barite results from its 2022 diamond drilling at the Indy Project in British Columbia.
PyroGenesis - PyroGenesis' STP torch for refrigerant destruction, hydrocracking and heating.

PyroGenesis to help global mining leader lower emissions

PyroGenesis Canada (TSX:PYR) signs a contract with a global mining supplier to apply its electric plasma torches towards emissions reduction.

Canadian biotech stock investigates potential weight loss drugs

FSD Pharma Inc. (CSE:HUGE) is expanding its pipeline into metabolic and related disorders including weight loss and liver health.